Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In some patients with parkinsonism and abnormal dopamine transporter (DAT) imaging using [I]FP-CIT single-photon emission computed tomography (SPECT), subsequent clinical evolution does not fit well with a neurodegenerative diagnosis.
Objective: The objective was to analyze the results of positron emission tomography (PET) with the recently developed DAT radioligand [F]FE-PE2I in patients with persistent diagnostic uncertainty despite an abnormal previous [I]FP-CIT SPECT scan.
Methods: This retrospective study included 19 patients with suspected parkinsonism and persistent diagnostic uncertainty after visually abnormal [I]FP-CIT SPECT who subsequently underwent [F]FE-PE2I PET (time between the two scans: 3.7 ± 2.2 years). Concordance between [I]FP-CIT SPECT and [F]FE-PE2I PET was determined after either purely visual assessment or semiquantitative analysis.
Results: In 74% of cases with visually abnormal [I]FP-CIT SPECT, [F]FE-PE2I PET was visually normal. After semiquantitative analysis, 63% of cases with abnormal [I]FP-CIT SPECT had normal [F]FE-PE2I PET.
Conclusions: [F]FE-PE2I PET is normal in the majority of cases, with persistent diagnostic uncertainty after abnormal [I]FP-CIT SPECT. © 2025 International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.30255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased frontal [I]FP-CIT binding in Parkinson's disease patients with self-reported REM sleep behavior disorder.
NPJ Parkinsons Dis
August 2025
Clinical Neurosciences, University of Turku, Turku, Finland.
Rapid eye movement (REM) sleep behavior disorder (RBD) is a frequent non-motor symptom of Parkinson's disease (PD) and a potential early marker of synucleinopathy-related neurodegeneration. While striatal dopaminergic dysfunction in PD-RBD has been extensively studied, the role of extrastriatal monoaminergic alterations -particularly those involving serotonin - remains poorly understood. In this study, 155 PD patients underwent [I]FP-CIT SPECT imaging to assess striatal and extrastriatal tracer binding, reflecting dopaminergic and broader monoaminergic function, respectively.
View Article and Find Full Text PDFFurther delineation of LRSAM1-related Charcot-Marie-Tooth type 2P with parkinsonism.
Eur J Med Genet
July 2025
Département de Neurologie, Hôpital Central, CHRU Nancy, 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France; Centre de référence des Pathologies Neuromusculaires Nord/Est/Ile de France, CHRU Nancy, 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France.
LRSAM1 pathogenic variations are linked to an axonal motor and sensory polyneuropathy known as Charcot-Marie-Tooth disease type 2P, but extra peripheral neurologic impairment is suspected. We report a patient with CMT2P and parkinsonism. We describe a 66-year-old man presenting with pes cavus, gait instability, and mild distal motor weakness.
View Article and Find Full Text PDFDiagnostic Value of Swallow Tail Sign at Brain MRI in Patients with Clinically Uncertain Parkinsonian Syndrome.
Radiology
July 2025
NIHR Nottingham Biomedical Research Centre, Mental Health & Clinical Neurosciences, Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Derby Rd, Nottingham NG7 2UH, United Kingdom.
Background Striatal dopaminergic deficits, established with iodine 123-2β-carbomethoxy-3β-(4-iodophenyl)--(3-fluoropropyl)-nortropan (I-FP-CIT) SPECT, support the diagnosis of Parkinson disease (PD) or atypical parkinsonian syndrome in clinical uncertainty. The swallow tail sign (STS) at susceptibility-weighted (SW) MRI helps differentiate patients with PD from controls, but its utility in clinically uncertain parkinsonian syndromes remains unclear. Purpose To compare the diagnostic performance of STS absence at SW MRI in diagnosing PD with that of I-FP-CIT SPECT in participants with clinically uncertain parkinsonian syndrome.
View Article and Find Full Text PDFNormal [F]FE-PE2I PET in Patients with Persistent Diagnostic Uncertainty after Abnormal [I]FP-CIT SPECT.
Mov Disord
August 2025
Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Background: In some patients with parkinsonism and abnormal dopamine transporter (DAT) imaging using [I]FP-CIT single-photon emission computed tomography (SPECT), subsequent clinical evolution does not fit well with a neurodegenerative diagnosis.
Objective: The objective was to analyze the results of positron emission tomography (PET) with the recently developed DAT radioligand [F]FE-PE2I in patients with persistent diagnostic uncertainty despite an abnormal previous [I]FP-CIT SPECT scan.
Methods: This retrospective study included 19 patients with suspected parkinsonism and persistent diagnostic uncertainty after visually abnormal [I]FP-CIT SPECT who subsequently underwent [F]FE-PE2I PET (time between the two scans: 3.
Synthesis and Preliminary Evaluation of an In Vivo Stable I-Labeled Deuterated Tropane for Mapping Dopamine Transporter.
J Labelled Comp Radiopharm
May 2025
School of Pharmaceutical Science, Inner Mongolia Medical University, Hohhot, China.
Dopamine transporter (DAT) is closely associated with neurodegenerative diseases such as Parkinson's disease (PD). To develop an in vivo stable radioligand targeting DAT, we synthesized a novel iodine-131-labeled tropane analog [I]1 with deuteration on both the N-fluoropropyl and 2β-carbomethoxy positions of the tropane scaffold and then biologically compared with the previously reported analog [I]FP-CIT-d with deuteration only on the N-fluoropropyl group. The radioligand [I]1 was obtained via a radioiodine-destannylation reaction with a radiochemical yield of ~95%, a radiochemical purity of > 99% and a molar activity of 12.
View Article and Find Full Text PDF